Amgen Inc. (AMGN)

In the past six months, Amgen's stock price has experienced fluctuations, reaching an all-time high of $390.29 on March 2, 2026, and decreasing to $344.54 by April 6, 2026. Over the past 12 months, the stock has increased by 19.41%. Recent analyst reports have focused on Amgen's upcoming first-quarter 2026 results, with some firms adjusting price targets and revenue estimates due to product mix and anticipated seasonal headwinds. Guggenheim lowered its Q1 2026 sales estimate but increased longer-term revenue estimates for products like Repatha and Uplizna, while noting weaker trends for Prolia, Otezla, and Xgeva. Amgen also announced successful Phase 3 trial results for certain products, and insider trading activity in November 2025 showed some officers selling shares.

Demand for Amgen's products and services exhibits some seasonality, which is common in the biotech and pharmaceutical industries. Historically, Amgen's first-quarter sales are typically the weakest due to seasonal patterns in patient volumes. This is influenced by factors such as changes in benefit plans, insurance reverifications, and increased co-pay expenses as U.S. patients work through deductibles at the beginning of the year. Demand for certain medications, like those for the common flu, typically rises in winter, while demand for hay fever medication increases in spring.

Amgen Inc. is a multinational biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics for serious illnesses. The company operates within the biotechnology sector and the biopharmaceutical industry, focusing on therapeutic areas including general medicine, rare diseases, inflammation, oncology/hematology, bone health, cardiovascular disease, and neuroscience. Amgen's major products include Prolia and Xgeva for osteoporosis and bone diseases, Enbrel for autoimmune diseases, Repatha for hyperlipidemia, Otezla for psoriasis and psoriatic arthritis, Tepezza for Graves' ophthalmopathy, Evenity for osteoporosis, Aimovig for migraine headaches, Neulasta and Neupogen for neutropenia, Epogen and Aranesp for anemia, Kyprolis and Blincyto for certain cancers, Vectibix for colorectal cancer, and Amjevita, a biosimilar.

Amgen has a significant global presence, operating in approximately 100 countries across North America, South America, Europe, Asia, Australia, and the Middle East. Its worldwide network supports research and development, manufacturing, clinical trials, commercial operations, sales and marketing, and distribution. The company's headquarters are in Thousand Oaks, California, USA. Amgen also has vital manufacturing and R&D facilities in locations such as Juncos, Puerto Rico, USA, and Cambridge, England, UK. In Ireland, Amgen has a commercial team in Santry and manufacturing facilities in Dún Laoghaire and Waterford, with the Dún Laoghaire site being its largest manufacturing facility outside the US.

Amgen has maintained a strong brand reputation over the past year. In the 2024 PatientView Corporate Reputation Survey, Amgen was ranked number one among pharma peer companies and third overall in the U.S. by patient organizations. The company also maintained these rankings from the previous year and received top marks in areas such as Integrity, Patient Centricity, Access to Medicines, Transparency in Pricing and Funding, Products of Benefit, and Long-Term Relationships. Amgen was once again included in Fortune's list of the World's Most Admired Companies, ranking 6th out of 17 in the biopharmaceutical peer group and showing improvement in the People Management category. Furthermore, Amgen was recognized as one of the 2026 World's Most Ethical Companies by Ethisphere, highlighting its commitment to ethical business practices.

Amgen's ownership structure is primarily institutional, with approximately 75.68% of the company's stock owned by institutional investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, Capital World Investors, Capital International Investors, Morgan Stanley, Geode Capital Management, Llc, Charles Schwab Investment Management Inc, Primecap Management Co/ca/, and Wells Fargo & Company/mn. As of December 30, 2025, The Vanguard Group, Inc. held 10.17% of shares, BlackRock, Inc. held 8.78%, and Capital Research and Management Company held 8.64%. Individual investors and public companies hold the remaining shares.